KBC Group’s Viking Therapeutics VKTX Stock Holding History

KBC Group’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$129K	Buy	3,960 +1,030	+35%	+$33.1K	﹤0.01%	1175
2025 Q4	$103K	Hold	2,930	–	–	﹤0.01%	1256
2025 Q3	$77K	Hold	2,930	–	–	﹤0.01%	1432
2025 Q2	$78K	Sell	2,930 -1,354	-32%	-$35.6K	﹤0.01%	1370
2025 Q1	$103K	Buy	4,284 +30	+0.7%	+$948	﹤0.01%	1469
2024 Q4	$171K	Buy	4,254 +1,257	+42%	+$71.7K	﹤0.01%	1219
2024 Q3	$190K	Buy	2,997 +473	+19%	+$27.8K	﹤0.01%	958
2024 Q2	$134K	Buy	2,524 +736	+41%	+$48.2K	﹤0.01%	1026
2024 Q1	$147K	Buy	+1,788	New	+$79.6K	﹤0.01%	949
2023 Q4	–	Sell	-1,445	Closed	-$16K	–	1909
2023 Q3	$16K	Buy	+1,445	New	+$20.7K	﹤0.01%	1905

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

KBC Group's VKTX Position: Q1 2026 in Review

KBC Group increased its Viking Therapeutics (VKTX) stake by 35% in Q1 2026, buying an estimated $33.1K and bringing the position to 3,960 shares worth $129K. The position accounts for ﹤0.01% of the portfolio, ranked #1175.

KBC Group first reported a position in VKTX in Q3 2023 and has held it in 10 quarters since. The position peaked at $190K in Q3 2024. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

KBC Group held 3,960 shares of Viking Therapeutics worth $129K as of Q1 2026.
KBC Group bought 1,030 Viking Therapeutics shares in Q1 2026, an estimated $33.1K.
Viking Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1175 holding.
KBC Group first reported a position in Viking Therapeutics in Q3 2023 and has held it in 10 quarters since.
KBC Group's Viking Therapeutics position peaked at $190K in Q3 2024.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.